372 related articles for article (PubMed ID: 37179582)
1. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
3. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
Duan M; Chi X; Xiao H; Liu X; Zhuang H
Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
[TBL] [Abstract][Full Text] [Related]
4. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B.
Sanai FM; Helmy A; Bzeizi KI; Babatin MA; Al-Qahtani A; Al-Ashgar HA; Al-Mdani AS; Al-Akwaa A; Almutharea S; Khan MQ; Alghamdi AS; Farah T; Al-Hamoudi W; Saadeh M; Abdo AA
J Viral Hepat; 2011 Jul; 18(7):e217-25. PubMed ID: 21692936
[TBL] [Abstract][Full Text] [Related]
5. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase.
Gao Y; Wang M; Liu X
Microbiol Spectr; 2024 Apr; 12(4):e0394123. PubMed ID: 38426768
[TBL] [Abstract][Full Text] [Related]
7. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
[TBL] [Abstract][Full Text] [Related]
8. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication.
Praneenararat S; Chamroonkul N; Sripongpun P; Kanngurn S; Jarumanokul R; Piratvisuth T
BMC Gastroenterol; 2014 Dec; 14():218. PubMed ID: 25523185
[TBL] [Abstract][Full Text] [Related]
9. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
[TBL] [Abstract][Full Text] [Related]
10. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
[TBL] [Abstract][Full Text] [Related]
11. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
[TBL] [Abstract][Full Text] [Related]
12. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
[TBL] [Abstract][Full Text] [Related]
14. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
[No Abstract] [Full Text] [Related]
15. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
16. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels.
Park JY; Park YN; Kim DY; Paik YH; Lee KS; Moon BS; Han KH; Chon CY; Ahn SH
J Viral Hepat; 2008 Aug; 15(8):615-21. PubMed ID: 18573162
[TBL] [Abstract][Full Text] [Related]
17. Impact of liver biopsy on the decision to treat patients with chronic hepatitis B genotype D virus infection.
Al-Qahtani AA; Al-Ashgar HI; Al Mana H; Al-Ahdal MN; Soliman Ali A; Hasanain AF; Helmy A
Intervirology; 2014; 57(5):248-53. PubMed ID: 24993859
[TBL] [Abstract][Full Text] [Related]
18. East Asia expert opinion on treatment initiation for chronic hepatitis B.
Kao JH; Hu TH; Jia J; Kurosaki M; Lim YS; Lin HC; Sinn DH; Tanaka Y; Wai-Sun Wong V; Yuen MF
Aliment Pharmacol Ther; 2020 Nov; 52(10):1540-1550. PubMed ID: 32951256
[TBL] [Abstract][Full Text] [Related]
19. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.
Huang DQ; Tran A; Yeh ML; Yasuda S; Tsai PC; Huang CF; Dai CY; Ogawa E; Ishigami M; Ito T; Kozuka R; Enomoto M; Suzuki T; Yoshimaru Y; Preda CM; Marin RI; Sandra I; Tran S; Quek SXZ; Khine HHTW; Itokawa N; Atsukawa M; Uojima H; Watanabe T; Takahashi H; Inoue K; Maeda M; Hoang JK; Trinh L; Barnett S; Cheung R; Lim SG; Trinh HN; Chuang WL; Tanaka Y; Toyoda H; Yu ML; Nguyen MH
Hepatology; 2023 Nov; 78(5):1558-1568. PubMed ID: 37184202
[TBL] [Abstract][Full Text] [Related]
20. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.
Kim GA; Han S; Choi GH; Choi J; Lim YS
Aliment Pharmacol Ther; 2020 Jun; 51(11):1169-1179. PubMed ID: 32291781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
